Multiomics STEP up in correlative analysis of response to CAR T cells

Mark B Leick^{1

2}, Marcela V Maus^{3

4}

Affiliations

¹ Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA. mvmaus@mgh.harvard.edu.
⁴ Harvard Medical School, Boston, MA, USA. mvmaus@mgh.harvard.edu.

Comment

Mark B Leick et al. Nat Rev Clin Oncol. 2023 May.

. 2023 May;20(5):285-286.

doi: 10.1038/s41571-023-00742-5.

Mark B Leick^{1

2}, Marcela V Maus^{3

4}

¹ Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA. mvmaus@mgh.harvard.edu.
⁴ Harvard Medical School, Boston, MA, USA. mvmaus@mgh.harvard.edu.

No abstract available

Comment on

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, Carleton M, Craig AFM, Younes SF, Sahaf B, Sheybani ND, Schroers-Martin JG, Liu CL, Oak JS, Jin MC, Beygi S, Hüttmann A, Hanoun C, Dührsen U, Westin JR, Khodadoust MS, Natkunam Y, Majzner RG, Mackall CL, Diehn M, Miklos DB, Alizadeh AA. Sworder BJ, et al. Cancer Cell. 2023 Jan 9;41(1):210-225.e5. doi: 10.1016/j.ccell.2022.12.005. Epub 2022 Dec 29. Cancer Cell. 2023. PMID: 36584673 Free PMC article.

1. Neelapu, S. S. et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 5, 4149–4155 (2021). - DOI - PubMed - PMC
1. Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021). - DOI - PubMed - PMC
1. Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848–1859 (2022). - DOI - PubMed - PMC
1. Good, Z. et al. Post-infusion CAR T_Reg cells identify patients resistant to CD19-CAR therapy. Nat. Med. 28, 1860–1871 (2022). - DOI - PubMed
1. Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878–1887 (2020). - DOI - PubMed - PMC